-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2864 Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged ≥ 60 Years Old with FLT3 Mutated Acute Myeloid Leukemia

Program: Oral and Poster Abstracts
Session: 613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Research, Acute Myeloid Malignancies, AML, elderly, Clinical Research, Combination therapy, Diseases, real-world evidence, Therapies, Myeloid Malignancies, Study Population, Human
Sunday, December 10, 2023, 6:00 PM-8:00 PM

Gaspar Aspas Requena, MD1*, Pierre Yves Dumas, MD, PhD2*, Rebeca Rodriguez Veiga, MD3*, Sarah Bertoli4*, Cristina Gil, MD5*, Celestine Simand, MD6*, Fernando Jesús Ramos-Ortega, MD7*, Pierre Peterlin8*, Josefina Serrano, MD9*, Rudy Birsen, MD10*, Teresa Bernal Del Castillo, MD, PhD11*, Emmanuelle Tavernier, MD12*, Mar Tormo, M.D.13, Martin Carre, MD14*, Maria Jose Garcia, MD15*, Adrien Contejean, MD16*, Rosalia Riaza Grau, MD17*, Corentin Orvain18*, Jose Antonio Pérez-Simón19, Esther Perez Santaolla, MD20*, Lauren Veronese, MD21*, Beatriz De Rueda Ciller, MD22*, Eric Delabesse, MD, PhD23*, Antonio Gutiérrez, MD, PhD24*, Ariane Mineur25*, Adolfo De La Fuente Burguera, MD26*, Romain Guieze, MD, PhD27*, Arnaud Pigneux, MD, PhD28*, Pau Montesinos, PhD, MD29*, Christian Recher, MD, PhD30* and David Matínez-Cuadrón, PhD31*

1Hématologie, Centre Hospitalier Universitaire Clermont-Ferrand, Clermont-Ferrand, France
2Department of Clinical Hematology, Bordeaux University Hospital, PESSAC, France
3Hospital Universitary i Politecnic La Fe, VALENCIA, ESP
4IUCT-Oncopole, Hematology Department, CHU de Toulouse - Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
5Hospital General Universitario de Alicante, Alicante, ESP
6Hematology, Institut de Cancerologie Strasbourg Europe (ICANS), Strasbourg, France
7Hospital Universitario de León, León, Spain
8Hematology Department, Hôpital Hotel Dieu, NANTES CEDEX 1, France
9Hospital Universitario Reina Sofía, IMIBIC, Cordoba, ESP
10Assistance Publique-Hopitaux De Paris, Hopital Cochin, Service D'héMatolo, Paris, FRA
11Hospital Universitario Central de Asturias, Oviedo, Spain
12Département d'hématologie Clinique et de Thérapie Cellulaire, CHU Saint-Etienne, Saint-Etienne, France
13Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria INCLIVA, Valencia, Spain
14Clinical Hematology Department, CHU Grenoble Alpes - Université Grenoble Alpes, Grenoble, France
15Complejo Hospitalario Torrecardenas, ALMERIA, ESP
16Hématologie, Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy, FRA
17Hospital Universitario Severo Ochoa, Madrid, ESP
18Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Angers, France
19Instituto de Biomedicina de Sevilla (IBIS), Servicio de Hematología, Hospital Universitario Virgen del Rocío and Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Sevilla, Sevilla, Spain
20Hospital Donostia, Donostia, Spain
21Centre Hospitalier Universitaire Clermont-Ferrand, Clermont Ferrrand, FRA
22Hospital Miguel Servet - Zaragoza, Zaragoza, Spain
23University Hospital of Toulouse, University of Toulouse 3, Center of Research On, Toulouse, NA, FRA
24Hematology Department, Hospital Universitario Son Espases, Palma de Mallorca, Spain
25Hôpital Haut-Lévèque, FILO Group Coordination, Pessac, France
26MD Anderson Cancer Center, Madrid, ESP
27Centre Hospitalier Universitaire Clermont-Ferrand, Clermont-Ferrand, France
28Hôpital Haut-Lévèque, Hematology Department, CHU Bordeaux, Pessac, France
29Hospital Universitari i Politecnic la Fe, Valencia, Spain
30Hematology Department, CHU de Toulouse - Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
31Hematology, Instituto de Investigación Sanitaria La Fe, Valencia, Spain

BACKGROUND: The prognosis of patients with acute myeloid leukemia (AML) varies depending on the presence of mutations in the FLT3 tyrosine kinase. Internal tandem duplications (ITD) and mutations in the tyrosine kinase domain (TKD) result in continuous activation of FLT3, leading to uncontrolled blast proliferation. Since the publication of the clinical trial CALGB 10603 (RATIFY), it has been established that adding midostaurine to intensive chemotherapy improves the overall survival (OS) of patients with mutated FLT3. However, it is worth noting that this study only included patients 18-59 years old. Subsequently, a phase II clinical trial (AMLSG 16-10 trial) conducted a subgroup analysis suggesting that midostaurine may also benefit to patients between 60 and 70 years of age. Nevertheless, these findings have not been studied in real-world clinical practice.

METHODS : This is multicentric non-interventional retrospective real-world study including patients ≥60 years of age with newly diagnosed FLT3-mutated AML treated with intensive chemotherapy and midostaurine (50 mg orally twice daily, d8-22) between 1st 2017 and July, 30th 2021 from the French Innovate Leukemia Organization (FILO) and the Programa Español de Tratamientos en Hematología (PETHEMA). The primary objective was to evaluate the efficacy of midostaurine in combination with intensive chemotherapy in patients over 60 years old. We assessed the rate of complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) after induction therapy, OS and event-free Survival (EFS).

RESULTS: A total of 191 patients (FILO Group 122 (63.9%); PETHEMA Group 69 (36.1%)), aged between 60 and 77 years, were enrolled in the study. The patients had a median age of 67.8 years (range 60.1; 77.6). Among them, 134 (70.2%) were aged less than 70 years, while 57 (29.8%) were aged 70 years or older. 159 (83.3%) had a performance status (ECOG) of 1 or lower, while 24 (12.6%) had an ECOG of 2 or higher.

151 (79.1%) had de novo acute myeloid leukemia (AML), and 40 (20.9%) had secondary AML at diagnosis. The median white blood cell count at diagnosis was 26.5 x 10^9/L [5.99; 107]. The median percentage of blasts in the bone marrow at diagnosis was 76% [55; 88.5]. The frequency of FLT3-ITD mutation was 154 (80.6%), FLT3-TKD mutation was 44 (23%), and double mutations were observed in 7 (3.7%) patients. The median FLT3 ITD/wt ratio was 57% [22.5 - 78]. 119 (62.3%) were NPM1 muted.

Regarding the intensive chemotherapy schedule in induction, 162 (84.8%) patients were treated with idarubicin-based regimens, 18 (9.4%) with daunorubicin-based regimens, and 8 (4.2%) with CPX-351. After induction, 150 (78.5%) of the patients achieved complete remission/complete remission with incomplete hematologic recovery (CR/CRi).

Of those patients, 96 (64%) proceeded to intensive chemotherapy schedule in consolidation, with 83 (86.5%) of them receiving midostaurine. In contrast, 32 (21.3%) received non-intensive chemotherapy consolidation, with 27 (84.4%) receiving midostaurine. Additionally, 37 (24.7%) of the patients who achieved CR/CRi after induction underwent a hematopoietic-cell transplantation (HCT), with 33 (89.2%) undergoing allogeneic HCT and 4 (12.1%) undergoing autologous HCT.

The median follow-up of the patients was 32 months. OS for the entire population was 23 months with a 2-years OS of 49.1% (95%CI: 41.5-56.7). Median EFS for the entire population was 11.1 months with a 2-years EFS of 37.1%. (95%CI: 29.6-44.5). For patients undergoing allogeneic HCT after achieving CR/CRi following induction, the median OS was not reached, with a 2-year OS of 69% (95% CI: 54.6-88.3). In contrast, for patients who achieved CR/CRi after induction but did not undergo allogeneic HCT, the OS was 32.6 months with a 2-year OS of 50.2% (95% CI: 48.4-68.2).

CONCLUSIONS: This real-life study suggests that the addition of midostaurine to intensive chemotherapy regimens in elderly patients could result in acceptable CRc, OS and EFS. In order to establish the benefit of midostaurin, we will compare these results with a historical control cohort.

Disclosures: Bertoli: Novartis: Honoraria; Abbvie: Honoraria, Other: Travel; BMS-Celgene: Honoraria; Jazz Pharmaceuticals: Honoraria, Other: Travel; Servier: Honoraria; Astellas: Honoraria. Bernal Del Castillo: Otsuka: Consultancy; Jazz: Consultancy; AbbVie: Consultancy. Tavernier: Abbvie: Honoraria. Tormo: Pfizer: Honoraria; BMS: Honoraria; Jannsen: Other: Support for attending meetings; SOBI: Other: Participation on Data Safety Monitoring Board; Gilead: Honoraria; MSD: Honoraria; Astellas: Honoraria; AbbVie: Honoraria; Jazz: Other: support for attending meetings. Pigneux: Astellas: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche: Research Funding; Servier: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings, Research Funding; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings; Gilead: Honoraria; Jazz Pharmaceuticals: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria; Pfizer: Membership on an entity's Board of Directors or advisory committees. Montesinos: INCYTE: Consultancy; OTSUKA: Consultancy; Janssen: Speakers Bureau; Astellas: Consultancy, Speakers Bureau; Celgene: Consultancy; NERVIANO: Consultancy; GILEAD: Consultancy; Novartis: Consultancy, Research Funding; Takeda: Consultancy, Research Funding; BEIGENE: Consultancy; Ryvu: Consultancy; Kura oncology: Consultancy; Menarini-Stemline: Consultancy, Research Funding; Jazz pharma: Consultancy, Research Funding, Speakers Bureau; Abbvie: Consultancy, Research Funding, Speakers Bureau; Pfizer: Consultancy, Research Funding, Speakers Bureau; BMS: Consultancy, Other, Research Funding; Daiichi Sankyo: Consultancy, Research Funding. Recher: Abbvie: Honoraria; Amgen: Research Funding; BMS: Other: Personal fees, Research Funding; Astellas: Other: Personal fees; Novartis: Other: Personal fees; Jazz Pharmaceuticals: Other: Personal fees, Research Funding; Servier: Other: Personal fees; MaatPharma: Research Funding; IQVIA: Research Funding; Takeda: Other: Personal fees.

*signifies non-member of ASH